Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S362.
doi: 10.21037/atm.2019.09.53.

The importance of antiandrogen in prostate cancer treatment

Camille Lanz  1 , Mostefa Bennamoun  2 , Petr Macek  1 , Xavier Cathelineau  1 , Rafael Sanchez-Salas  1
Affiliations
Editorial

The importance of antiandrogen in prostate cancer treatment

Camille Lanz et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Overall survival. Survival curve from: TITAN trial - ENZAMET trial - LATITUDE trial - The new England Journal of Medicine. ARCHES trial - Report from ASCO GU 2019 (20,22,23). ADT, androgen deprivation therapy; NR, not reached; ENZA, enzalutamide; PBO, Placebo.
See this image and copyright information in PMC

Comment on

  • Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Clinical Trial.

References

    1. Crawford ED, Schellhammer PF, McLeod DG, et al. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol 2018;200:956-66. 10.1016/j.juro.2018.04.083 - DOI - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. 10.1056/NEJMoa1014618 - DOI - PMC - PubMed
    1. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. 10.1056/NEJMoa041318 - DOI - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. 10.1056/NEJMoa040720 - DOI - PubMed
    1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. 10.1056/NEJMoa1207506 - DOI - PubMed